- 作者: Yan-Ruide Li, Tyler Halladay & Lili Yang
- 作者服務機構: 1.Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, 90095, USA 2.Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, 90095, USA 3.Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, USA 4.Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, 90095, USA
- 中文摘要:
- 英文摘要:
Cell-based immunotherapies (CBIs), notably exemplified by chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy, have emerged as groundbreaking approaches for cancer therapy. Nevertheless, akin to various other therapeutic modalities, tumor cells employ counterstrategies to manifest immune evasion, thereby circumventing the impact of CBIs. This phenomenon is facilitated by an intricately immunosuppression entrenched within the tumor microenvironment (TME). Principal mechanisms underpinning tumor immune evasion from CBIs encompass loss of antigens, downregulation of antigen presentation, activation of immune checkpoint pathways, initiation of anti-apoptotic cascades, and induction of immune dysfunction and exhaustion. In this review, we delve into the intrinsic mechanisms underlying the capacity of tumor cells to resist CBIs and proffer prospective stratagems to navigate around these challenges. - 中文關鍵字:
- 英文關鍵字: Immune evasion, Cell-based immunotherapies (CBIs), Chimeric antigen receptor (CAR), CAR-engineered T (CAR-T) cell therapy, Tumor microenvironment (TME), Immune checkpoint proteins, Tumor heterogeneity